Kun Zhang1, Jiaojiao Zhou1,2, Xuan Zhu1,2, Meng Luo1, Chunjing Xu1, JieKai Yu2, Mei Deng1, Shu Zheng1,2, Yiding Chen3,4. 1. Department of Surgical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jie-Fang Rd, Hangzhou, 310009, Zhejiang, China. 2. The Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, 88 Jie-Fang Rd, Hangzhou, 310009, Zhejiang, China. 3. Department of Surgical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jie-Fang Rd, Hangzhou, 310009, Zhejiang, China. ydchen@zju.edu.cn. 4. The Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, 88 Jie-Fang Rd, Hangzhou, 310009, Zhejiang, China. ydchen@zju.edu.cn.
Abstract
BACKGROUND: PALB2 (Partner and Localizer of BRCA2) is recently recognized as a breast cancer predisposition gene. Germline loss-of-function mutations in PALB2 lead to increased breast cancer risk. Since the germline mutation frequency of PALB2 is much less than BRCA1/2, the distinct mutation spectrum of PALB2 is still obscure. To verify the utility of PALB2 genetic testing in Chinese population, we assessed the mutational frequency, spectrum, and predictors of the PALB2 gene in a sequential series of Chinese breast cancer patients from our Research DNA Bank. METHODS: We examined breast cancer samples (n = 2279) collected from 2000 through 2016 from Chinese patients who agreed to participate in research DNA banking. To identify the mutations, complete coding sequence and intron-exon boundaries of PALB2 were screened with Next-Generation Sequencing. Personal and family histories were synchronously collected for mutation identification. RESULTS: Among the 2279 breast cancer patients, 305 patients were familial breast cancer cases and the rest 1967 patients were sporadic breast cancer cases. PALB2 loss-of-function mutation carriers accounted for 1.31% (n = 4) and 0.56% (n = 11) in familial and sporadic breast cancer cohort separately. In total, 30 missenses, four nonsenses, three frameshifts, three splicings, and one inframe deletions of PALB2 were identified in this study. Among the deleterious mutations, PALB2 c.1744C>T, c.2748+1G>A, c.2749-1G>C, c.3114-1G>A were newly identified in sporadic breast cancer, and c.3271delC newly found in familial breast cancer. Based on in silico analysis, we found two potentially damaging missense variants with high frequency: c.1213C>G, c.3054G>C, and classified six new potentially damaging missense variants. CONCLUSIONS: Our data presented the germline mutation status of PALB2 in Chinese breast cancer patients, suggesting that loss-of-function germline mutations of PALB2 are important in both familial and sporadic breast cancer. Clinically, these data may be helpful in genetic counseling of breast cancer patients with PALB2 germline mutation.
BACKGROUND:PALB2 (Partner and Localizer of BRCA2) is recently recognized as a breast cancer predisposition gene. Germline loss-of-function mutations in PALB2 lead to increased breast cancer risk. Since the germline mutation frequency of PALB2 is much less than BRCA1/2, the distinct mutation spectrum of PALB2 is still obscure. To verify the utility of PALB2 genetic testing in Chinese population, we assessed the mutational frequency, spectrum, and predictors of the PALB2 gene in a sequential series of Chinese breast cancerpatients from our Research DNA Bank. METHODS: We examined breast cancer samples (n = 2279) collected from 2000 through 2016 from Chinese patients who agreed to participate in research DNA banking. To identify the mutations, complete coding sequence and intron-exon boundaries of PALB2 were screened with Next-Generation Sequencing. Personal and family histories were synchronously collected for mutation identification. RESULTS: Among the 2279 breast cancerpatients, 305 patients were familial breast cancer cases and the rest 1967 patients were sporadic breast cancer cases. PALB2 loss-of-function mutation carriers accounted for 1.31% (n = 4) and 0.56% (n = 11) in familial and sporadic breast cancer cohort separately. In total, 30 missenses, four nonsenses, three frameshifts, three splicings, and one inframe deletions of PALB2 were identified in this study. Among the deleterious mutations, PALB2 c.1744C>T, c.2748+1G>A, c.2749-1G>C, c.3114-1G>A were newly identified in sporadic breast cancer, and c.3271delC newly found in familial breast cancer. Based on in silico analysis, we found two potentially damaging missense variants with high frequency: c.1213C>G, c.3054G>C, and classified six new potentially damaging missense variants. CONCLUSIONS: Our data presented the germline mutation status of PALB2 in Chinese breast cancerpatients, suggesting that loss-of-function germline mutations of PALB2 are important in both familial and sporadic breast cancer. Clinically, these data may be helpful in genetic counseling of breast cancerpatients with PALB2 germline mutation.
Entities:
Keywords:
Breast cancer; Genetic sequencing; Germline mutations; PALB2
Authors: Xin Huang; Di Shao; Huanwen Wu; Changbin Zhu; Dan Guo; Yidong Zhou; Chang Chen; Yan Lin; Tao Lu; Bin Zhao; Changjun Wang; Qiang Sun Journal: Front Oncol Date: 2020-10-30 Impact factor: 6.244